To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

Quarterly results

rupeeShow figures in :
rupeeShow figures in :

Quarterly results

Quarter ended on June 30, 2025Data in Crores of INR
Revenue
1.33K-2.47% from last year
Operating profits
632.70-25.82% from last year
Net income
480.30-28.15% from last year

Financial reports

Data is unavailable

INCOME STATEMENTinfo2
Data in Crores of INR

Data is unavailable

BALANCE SHEETinfo2
Data in Crores of INR
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012FY 2011FY 2010FY 2008FY 2007FY 2006FY 2005
Net worth7607.005853.104873.804263.604121.603773.503489.003072.201649.301295.70846.05725.88533.54473.63352.43305.74218.28180.30147.85113.65
Fixed assets2698.002490.802426.902311.802023.201584.401227.201018.60833.00710.10709.97644.74582.75319.56270.16261.80210.45154.73136.3696.18
Debt273.10363.20165.00404.00265.80314.20386.30173.20221.60112.60311.84240.45337.71258.65219.97119.5094.1376.4480.05111.23
docView detailed balance sheet
arrow
CASH FLOWinfo2
Data in Crores of INR
FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013FY2012FY2011FY2010
Operating1696.801211.60849.1046.50298.80417.30668.80463.60345.80112.2092.67144.0361.1964.9436.9977.37
Investing -1414.50-1032.70-477.10-5.30-103.30-167.00-612.20-1115.50-299.40-175.50-114.75-108.92-107.07-126.94-88.78-60.85
Financing -210.70-246.90-363.0034.80-185.70-250.80-50.90650.90-47.70154.0029.08-35.2726.3162.7877.10-34.14

Financial ratios

Profitability ratiosinfo2
ROA24.35%
ROE27.98%
ROCE32.85%
EPS105.33%
Net profit margin42.52%
Operating profit margin53.54%
Dividend per share6%
Operational ratiosinfo2
Quick ratio4.77%
Current ratio5.59%
Interest coverage96.87%
Assets turnover0.62%
Debt to equity0.04%
Valuation ratiosinfo2
P/E ratio9.13%
P/B ratio1.92%
Dividend yield0.69%
EV/EBITDA
Natco Pharma Limited is a vertically integrated and RD focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company manufactures API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets. In the API segment, company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. It is also engaged in contract manufacturing business, whereby it undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. It has diversified into the business of crop health sciences to leverage is skills in organic chemistry.
personal

Grow your wealth with more research recommendations

+91